Literature DB >> 23179809

[Preservatives in ophthalmology].

E M Messmer1.   

Abstract

Preservatives are a legal requirement for eye drops in multidose containers. Moreover, they are necessary for stabilization and intraocular penetration for a number of ophthalmic preparations. Most preservatives act in a relatively unspecific manner as detergents or by oxidative mechanisms and thereby cause side effects at the ocular surface. They may also affect the lens, trabecular meshwork and the retina. Benzalkonium chloride is the most commonly used preservative in ophthalmology and is more toxic than other or newer preservatives, such as polyquaternium-1 (Polyquad), sodium perborate, oxychloro-complex (Purite®) and SofZia. Preservative-free topical medication is highly recommended for patients with ocular surface disease, frequent eye drop administration, proven allergy to preservatives and contact lens wear.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179809     DOI: 10.1007/s00347-012-2638-4

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  33 in total

Review 1.  Microbial contamination of eye drops.

Authors:  H Taşli; G Coşar
Journal:  Cent Eur J Public Health       Date:  2001-08       Impact factor: 1.163

2.  Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.

Authors:  Richard A Lewis; Gregory J Katz; Mark J Weiss; Theresa A Landry; Jaime E Dickerson; John E James; Steven Y Hua; E Kenneth Sullivan; Dawnelle B Montgomery; David T Wells; Michael V W Bergamini
Journal:  J Glaucoma       Date:  2007-01       Impact factor: 2.503

3.  The dilution of benzalkonium chloride (BAK) in the tear film.

Authors:  Mitchell H Friedlaender; Daphne Breshears; Bahram Amoozgar; Heather Sheardown; Michelle Senchyna
Journal:  Adv Ther       Date:  2006 Nov-Dec       Impact factor: 3.845

4.  [Preservative-free timolol eye drops--surface-anesthetic effect and local compatibility].

Authors:  H Höh
Journal:  Ophthalmologica       Date:  1990       Impact factor: 3.250

5.  Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study.

Authors:  David C Herman; Mae O Gordon; Julia A Beiser; Leo T Chylack; Kathleen A Lamping; Oliver D Schein; Joern B Soltau; Michael A Kass
Journal:  Am J Ophthalmol       Date:  2006-11       Impact factor: 5.258

6.  Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.

Authors:  David A Ammar; Robert J Noecker; Malik Y Kahook
Journal:  Adv Ther       Date:  2010-10-07       Impact factor: 3.845

7.  Corneal and conjunctival changes caused by commonly used glaucoma medications.

Authors:  Robert J Noecker; Lisa A Herrygers; Raana Anwaruddin
Journal:  Cornea       Date:  2004-07       Impact factor: 2.651

8.  Ocular symptoms and signs with preserved and preservative-free glaucoma medications.

Authors:  N Jaenen; C Baudouin; P Pouliquen; G Manni; A Figueiredo; T Zeyen
Journal:  Eur J Ophthalmol       Date:  2007 May-Jun       Impact factor: 2.597

9.  Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol.

Authors:  Yoko Goto; Nobuhiro Ibaraki; Kensaku Miyake
Journal:  Arch Ophthalmol       Date:  2003-06

10.  ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy.

Authors:  Kensaku Miyake; Nobuhiro Ibaraki; Yoko Goto; Shin Oogiya; Junko Ishigaki; Ichiro Ota; Sampei Miyake
Journal:  J Cataract Refract Surg       Date:  2003-09       Impact factor: 3.351

View more
  3 in total

Review 1.  The pathophysiology, diagnosis, and treatment of dry eye disease.

Authors:  Elisabeth M Messmer
Journal:  Dtsch Arztebl Int       Date:  2015-01-30       Impact factor: 5.594

2.  Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease--A Prospective, Multicenter Noninterventional Study.

Authors:  Philipp Steven; Dieter Scherer; Sonja Krösser; Michael Beckert; Claus Cursiefen; Thomas Kaercher
Journal:  J Ocul Pharmacol Ther       Date:  2015-08-21       Impact factor: 2.671

3.  Ocular surface alterations and topical antiglaucomatous therapy: a review.

Authors:  Alessandro G Actis; Teresa Rolle
Journal:  Open Ophthalmol J       Date:  2014-10-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.